Rationale for the development of an engineered sporozoite malaria vaccine.
Nussenzweig
V
V
Department of Pathology, New York University Medical Center, New York 10016.
Nussenzweig
R S
RS
D000818:Animals; D000953:Antigens, Protozoan / Q000235:genetics; D006801:Humans; D007167:Immunotherapy; D008288:Malaria / Q000276:immunology / Q000517:prevention & control*; D010961:Plasmodium / Q000235:genetics / Q000254:growth & development / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D014614:Vaccines, Synthetic / Q000627:therapeutic use
D000953:Antigens, Protozoan; D014614:Vaccines, Synthetic